Dr. Juan Manuel Sepúlveda Sánchez

Facultativo Especialista de Área en Oncología Médica del Hospital Universitario 12 de Octubre

Presidente del Grupo Español de Neurooncología (GEINO).

Miembro de Sociedad Española de Oncología Médica (SEOM).

Colaborador IMIBIC y activo en diversos ensayos clínicos e investigaciones.

Subcomisión de tumores sistema nervioso central (fundador)

Publicaciones

Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas. Pérez-García VM, Ayala-Hernández LE, Belmonte-Beitia J, Schucht P, Murek M, Raabe A, Sepúlveda J. PLoS Comput Biol. 2019 Jul 15;15(7):e1006778. doi: 10.1371/journal.pcbi.1006778. eCollection 2019 Jul. PMID: 31306418
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Ciruelos E, Apellániz-Ruiz M, Cantos B, Martinez-Jáñez N, Bueno-Muiño C, Echarri MJ, Enrech S, Guerra JA, Manso L, Pascual T, Dominguez C, Gonzalo JF, Sanz JL, Rodriguez-Antona C, Sepúlveda JM. Oncologist. 2019 Apr 25.
Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A. Clin Transl Oncol. 2019 Mar 15. doi: 10.1007/s12094-019-02070-6.
Dacomitinib: an investigational drug for the treatment of glioblastoma. Sepúlveda JM, Sánchez-Gómez P, Vaz Salgado MÁ, Gargini R, Balañá C. Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225. Epub 2018 Oct 5.
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Sepúlveda-Sánchez JM, Muñoz Langa J, Arráez MÁ, Fuster J, Hernández Laín A, Reynés G, Rodríguez González V, Vicente E, Vidal Denis M, Gallego Ó. Clin Transl Oncol. 2018 Jan;20(1):3-15. doi: 10.1007/s12094-017-1790-3
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, Gil-Gil M, Reynés G, Gallego Ó, Martínez-García M, Vicente E, Quindós M, Luque R, Ramos A, Ruano Y, Pérez-Segura P, Benavides M, Sánchez-Gómez P, Hernández-Laín A. Neuro Oncol. 2017 Oct 19;19(11):1522-1531.
Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study. Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynes G and Belenguer A. Oncology Letters 2017. Jun;13(6):4093-4100.
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. Eur Urol Focus. 2017 Apr;3(2-3):280-286.